• Profile
Close

Real‐world outcomes of advanced melanoma patients not represented in phase III trials

International Journal of Cancer Jul 09, 2020

van Zeijl MCT, Ismail RK, de Wreede LC, et al. - Researchers used nationwide population‐based registry to provide evidence on systemically treated patients with advanced melanoma not represented in phase III trials to support clinical decision‐making. Analysis were conducted on advanced melanoma individuals diagnosed between 2014 and 2017 in the Netherlands, treated with immune‐ or targeted therapy, who met ≥ 1 trial exclusion criteria. Of the 2,536 systemically treated patients with advanced melanoma, 1,004 (40%) patients were not eligible for Phase III trials. The conditional inference survival tree displayed the strongest prognostic covariate for survival was lactate dehydrogenase (LDH), followed by Eastern Cooperative Oncology Group Performance Score (ECOG PS). Patient prognosis with LDH of > 500 U/L is poor, but long‐term survival is possible. In real‐world, the prognosis of ineligible patients with advanced melanoma was very heterogeneous and highly dependent on LDH value, ECOG PS, and symptomatic BM.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay